Our goal is to provide the highest level of care to all of our patients, and that includes offering novel treatments before they are widely available. If you are a cancer patient, you may be eligible for one of our current clinical trials.

Bladder Cancer

  • Stage IV
  • Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation 
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • Afatinib (BIBW 2992) in Advanced Refractory Urothelial Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Breast Cancer

  • Stage IB - Stage IIIA
  • A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage I-IIIC
  • The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage I-III
  • Optimizing Endocrine Therapy through Motivational Interviewing and Text Interventions
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IIIA
  • A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage T2 - IIIC 
  • Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IB-IIIC
  • A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage — Stage 0-pTis
  • Cluster Randomized Controlled Trial Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ–Making Informed Choices on Incorporating Chemoprevention into Care MiCHOICE
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV or Unresectable Stage III
  • A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-bound Paclitaxel (nab-paclitaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • Phase II Study of Pembrolizumab and Mifepristone in Patients with Advanced HER2-Negative Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Colon/Rectal Cancer

  • Stage III
  • Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage III - IV
  • Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage II - III
  • Duloxetine To Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II To Phase III Study
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IIA
  • Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage 0 - III
  • A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Gastric Cancer (Stomach Cancer)

  • Stage IB - IIIC
  • PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Gynecologic Cancer

  • Relapsed / Refractory
  • Randomized Phase II/III Study of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Head and Neck Cancer

  • Stage IVA, IVB, and select Stage III
  • A Randomized, Double-Blind Phase II Study of Pembrolizumab Versus Placebo in Patients with Head and Neck Cancers at High Risk for Recurrence or Low-Volume Residual Disease (The Pathway Study)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients with Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Kidney Cancer

  • Stage IV
  • Nivolumab and Ipilimumab followed by Nivolumab versus VEGF TKI Cabozantinib with Nivolumab: Phase III Trial in Metastatic Untreated Renal Cell Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Leukemia

  • Stage I - IV
  • A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) 
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Any Newly Diagnosed
  • Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Lung Cancer

  • Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IIIB-IV
  • Study Title A Phase 1B Study of Venetoclax in Combination with Pembrolizumab in Subjects with Previously Untreated Non-Small Cell Lung Cancer Whose Tumors have High PD-L1 Expression
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV or Recurrent Metastatic 
  • Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patient’s Choice)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • Randomized Phase 3 Study of Combination AZD9291 (Osimertinib) and Bevacizumab versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

  • Stage IIIB
  • Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Stage IV
  • Master Protocol to Evaluate Biomarker-Drive Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage III / IV
  • Phase II Randomized Study of Maintenance Atezolizumab versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination with Vorolanib in Patients with Refractory Thoracic Tumors
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Lymphoma

  • Stage III-IV
  • A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age > 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Stage varies 
  • Phase II Study of Pembrolizumab in Combination with R-CHOP for Patients with Untreated, High-Risk, Non-Germinal Center-Derived DLBCL
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Phase II Study of Pembrolizumab for PD-L1 Gene-Altered, Relapsed/Refractory DLBCL
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Myelodysplastic Syndrome (MDS)

  • Stage – not applicable
  • A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage – not applicable
  • Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Multiple Myeloma

  • High-Risk SMM
  • Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Open-label, Single-arm, Phase 2 Study of Initial Treatment with Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Ovarian Cancer

  • Stage III - IV
  • A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Pancreas Cancer

  • Creon® (pancrelipase) therapy for subjects with exocrine pancreatic insufficiency (EPI) due to pancreatic cancer: A double-blind, randomized, parallel design with 2 dose cohorts of pancrelipase in resected pancreatic cancer subjects and an open-label single dose cohort in non-resected pancreatic cancer subjects
  • If you are eligible and would like to participate, please contact the research staff at 708-915-4673 (HOPE) or send an email to clinicaltrials@ingalls.org.
  • Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Prostate Cancer

  • Stage IV
  • CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Any pT stage
  • Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Solid Tumors and Multiple Disease Sites

An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

  • Locally Advanced / Stage IV
  • Phase 1b Dose‑Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors 
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Recurrent / Metastatic Stage IV
  • Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

  •  Any Stage
  • A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 

Biobanking

  • Protocol for Lymphoma Program Biobank
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Any Stage 
  • Genomic Analysis to Identify Correlates of the Inflamed Tumor-Phenotype in Patients with Advanced Malignancies Receiving Immunotherapy
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.